The global market for Drugs for Vaginal Fungal Infections was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Drugs for Vaginal Fungal Infections, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Drugs for Vaginal Fungal Infections by region & country, by Type, and by Application.

The Drugs for Vaginal Fungal Infections market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Vaginal Fungal Infections.

Market Segmentation

Scope of Drugs for Vaginal Fungal Infections - Market Report

Report Metric	Details
Report Name	Drugs for Vaginal Fungal Infections - Market
CAGR	5%
Segment by Type:	Fluconazole Nystatin Flucytosine Clotrimazole Others
Segment by Application	Hospital Clinic Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer Inc., Bausch Health Companies Inc, ANl Pharmaceuticals, Inc, Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC Medical AB, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, SCYNEXIS,Inc., Basilea Pharmaceutica Ltd., Astellas Pharma lnc., Grupo Ferrer Internacional,S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Drugs for Vaginal Fungal Infections manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Drugs for Vaginal Fungal Infections in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Drugs for Vaginal Fungal Infections in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Drugs for Vaginal Fungal Infections - Market report?

Ans: The main players in the Drugs for Vaginal Fungal Infections - Market are Pfizer Inc., Bausch Health Companies Inc, ANl Pharmaceuticals, Inc, Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC Medical AB, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, SCYNEXIS,Inc., Basilea Pharmaceutica Ltd., Astellas Pharma lnc., Grupo Ferrer Internacional,S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc.

What are the Application segmentation covered in the Drugs for Vaginal Fungal Infections - Market report?

Ans: The Applications covered in the Drugs for Vaginal Fungal Infections - Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Drugs for Vaginal Fungal Infections - Market report?

Ans: The Types covered in the Drugs for Vaginal Fungal Infections - Market report are Fluconazole, Nystatin, Flucytosine, Clotrimazole, Others

1 Market Overview

1.1 Drugs for Vaginal Fungal Infections Product Introduction

1.2 Global Drugs for Vaginal Fungal Infections Market Size Forecast

1.3 Drugs for Vaginal Fungal Infections Market Trends & Drivers

1.3.1 Drugs for Vaginal Fungal Infections Industry Trends

1.3.2 Drugs for Vaginal Fungal Infections Market Drivers & Opportunity

1.3.3 Drugs for Vaginal Fungal Infections Market Challenges

1.3.4 Drugs for Vaginal Fungal Infections Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Drugs for Vaginal Fungal Infections Players Revenue Ranking (2023)

2.2 Global Drugs for Vaginal Fungal Infections Revenue by Company (2019-2024)

2.3 Key Companies Drugs for Vaginal Fungal Infections Manufacturing Base Distribution and Headquarters

2.4 Key Companies Drugs for Vaginal Fungal Infections Product Offered

2.5 Key Companies Time to Begin Mass Production of Drugs for Vaginal Fungal Infections

2.6 Drugs for Vaginal Fungal Infections Market Competitive Analysis

2.6.1 Drugs for Vaginal Fungal Infections Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Drugs for Vaginal Fungal Infections Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Vaginal Fungal Infections as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Fluconazole

3.1.2 Nystatin

3.1.3 Flucytosine

3.1.4 Clotrimazole

3.1.5 Others

3.2 Global Drugs for Vaginal Fungal Infections Sales Value by Type

3.2.1 Global Drugs for Vaginal Fungal Infections Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Drugs for Vaginal Fungal Infections Sales Value, by Type (2019-2030)

3.2.3 Global Drugs for Vaginal Fungal Infections Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Clinic

4.1.3 Others

4.2 Global Drugs for Vaginal Fungal Infections Sales Value by Application

4.2.1 Global Drugs for Vaginal Fungal Infections Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Drugs for Vaginal Fungal Infections Sales Value, by Application (2019-2030)

4.2.3 Global Drugs for Vaginal Fungal Infections Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Drugs for Vaginal Fungal Infections Sales Value by Region

5.1.1 Global Drugs for Vaginal Fungal Infections Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Drugs for Vaginal Fungal Infections Sales Value by Region (2019-2024)

5.1.3 Global Drugs for Vaginal Fungal Infections Sales Value by Region (2025-2030)

5.1.4 Global Drugs for Vaginal Fungal Infections Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Drugs for Vaginal Fungal Infections Sales Value, 2019-2030

5.2.2 North America Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Drugs for Vaginal Fungal Infections Sales Value, 2019-2030

5.3.2 Europe Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Drugs for Vaginal Fungal Infections Sales Value, 2019-2030

5.4.2 Asia Pacific Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Drugs for Vaginal Fungal Infections Sales Value, 2019-2030

5.5.2 South America Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Drugs for Vaginal Fungal Infections Sales Value, 2019-2030

5.6.2 Middle East & Africa Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Drugs for Vaginal Fungal Infections Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Drugs for Vaginal Fungal Infections Sales Value

6.3 United States

6.3.1 United States Drugs for Vaginal Fungal Infections Sales Value, 2019-2030

6.3.2 United States Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Drugs for Vaginal Fungal Infections Sales Value, 2019-2030

6.4.2 Europe Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Drugs for Vaginal Fungal Infections Sales Value, 2019-2030

6.5.2 China Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030

6.5.3 China Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Drugs for Vaginal Fungal Infections Sales Value, 2019-2030

6.6.2 Japan Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Drugs for Vaginal Fungal Infections Sales Value, 2019-2030

6.7.2 South Korea Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Drugs for Vaginal Fungal Infections Sales Value, 2019-2030

6.8.2 Southeast Asia Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Drugs for Vaginal Fungal Infections Sales Value, 2019-2030

6.9.2 India Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030

6.9.3 India Drugs for Vaginal Fungal Infections Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Pfizer Inc.

7.1.1 Pfizer Inc. Profile

7.1.2 Pfizer Inc. Main Business

7.1.3 Pfizer Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.1.4 Pfizer Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.1.5 Pfizer Inc. Recent Developments

7.2 Bausch Health Companies Inc

7.2.1 Bausch Health Companies Inc Profile

7.2.2 Bausch Health Companies Inc Main Business

7.2.3 Bausch Health Companies Inc Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.2.4 Bausch Health Companies Inc Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.2.5 Bausch Health Companies Inc Recent Developments

7.3 ANl Pharmaceuticals, Inc

7.3.1 ANl Pharmaceuticals, Inc Profile

7.3.2 ANl Pharmaceuticals, Inc Main Business

7.3.3 ANl Pharmaceuticals, Inc Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.3.4 ANl Pharmaceuticals, Inc Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.3.5 Hikma Pharmaceuticals Plc Recent Developments

7.4 Hikma Pharmaceuticals Plc

7.4.1 Hikma Pharmaceuticals Plc Profile

7.4.2 Hikma Pharmaceuticals Plc Main Business

7.4.3 Hikma Pharmaceuticals Plc Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.4.4 Hikma Pharmaceuticals Plc Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.4.5 Hikma Pharmaceuticals Plc Recent Developments

7.5 Lupin Limited

7.5.1 Lupin Limited Profile

7.5.2 Lupin Limited Main Business

7.5.3 Lupin Limited Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.5.4 Lupin Limited Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.5.5 Lupin Limited Recent Developments

7.6 Mycovia Pharmaceuticals, Inc.

7.6.1 Mycovia Pharmaceuticals, Inc. Profile

7.6.2 Mycovia Pharmaceuticals, Inc. Main Business

7.6.3 Mycovia Pharmaceuticals, Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.6.4 Mycovia Pharmaceuticals, Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.6.5 Mycovia Pharmaceuticals, Inc. Recent Developments

7.7 Glenmark Pharmaceuticals Limited

7.7.1 Glenmark Pharmaceuticals Limited Profile

7.7.2 Glenmark Pharmaceuticals Limited Main Business

7.7.3 Glenmark Pharmaceuticals Limited Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.7.4 Glenmark Pharmaceuticals Limited Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.7.5 Glenmark Pharmaceuticals Limited Recent Developments

7.8 Unique Pharmaceuticals

7.8.1 Unique Pharmaceuticals Profile

7.8.2 Unique Pharmaceuticals Main Business

7.8.3 Unique Pharmaceuticals Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.8.4 Unique Pharmaceuticals Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.8.5 Unique Pharmaceuticals Recent Developments

7.9 PEPTONIC Medical AB

7.9.1 PEPTONIC Medical AB Profile

7.9.2 PEPTONIC Medical AB Main Business

7.9.3 PEPTONIC Medical AB Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.9.4 PEPTONIC Medical AB Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.9.5 PEPTONIC Medical AB Recent Developments

7.10 Aurobindo Pharma Limited

7.10.1 Aurobindo Pharma Limited Profile

7.10.2 Aurobindo Pharma Limited Main Business

7.10.3 Aurobindo Pharma Limited Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.10.4 Aurobindo Pharma Limited Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.10.5 Aurobindo Pharma Limited Recent Developments

7.11 Dr. Reddy's Laboratories

7.11.1 Dr. Reddy's Laboratories Profile

7.11.2 Dr. Reddy's Laboratories Main Business

7.11.3 Dr. Reddy's Laboratories Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.11.4 Dr. Reddy's Laboratories Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.11.5 Dr. Reddy's Laboratories Recent Developments

7.12 SCYNEXIS,Inc.

7.12.1 SCYNEXIS,Inc. Profile

7.12.2 SCYNEXIS,Inc. Main Business

7.12.3 SCYNEXIS,Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.12.4 SCYNEXIS,Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.12.5 SCYNEXIS,Inc. Recent Developments

7.13 Basilea Pharmaceutica Ltd.

7.13.1 Basilea Pharmaceutica Ltd. Profile

7.13.2 Basilea Pharmaceutica Ltd. Main Business

7.13.3 Basilea Pharmaceutica Ltd. Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.13.4 Basilea Pharmaceutica Ltd. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.13.5 Basilea Pharmaceutica Ltd. Recent Developments

7.14 Astellas Pharma lnc.

7.14.1 Astellas Pharma lnc. Profile

7.14.2 Astellas Pharma lnc. Main Business

7.14.3 Astellas Pharma lnc. Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.14.4 Astellas Pharma lnc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.14.5 Astellas Pharma lnc. Recent Developments

7.15 Grupo Ferrer Internacional,S.A.

7.15.1 Grupo Ferrer Internacional,S.A. Profile

7.15.2 Grupo Ferrer Internacional,S.A. Main Business

7.15.3 Grupo Ferrer Internacional,S.A. Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.15.4 Grupo Ferrer Internacional,S.A. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.15.5 Grupo Ferrer Internacional,S.A. Recent Developments

7.16 Pacgen Life Science Corporation

7.16.1 Pacgen Life Science Corporation Profile

7.16.2 Pacgen Life Science Corporation Main Business

7.16.3 Pacgen Life Science Corporation Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.16.4 Pacgen Life Science Corporation Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.16.5 Pacgen Life Science Corporation Recent Developments

7.17 NovaDigm Therapeutics, Inc.

7.17.1 NovaDigm Therapeutics, Inc. Profile

7.17.2 NovaDigm Therapeutics, Inc. Main Business

7.17.3 NovaDigm Therapeutics, Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.17.4 NovaDigm Therapeutics, Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.17.5 NovaDigm Therapeutics, Inc. Recent Developments

7.18 Cidara Therapeutics, Inc.

7.18.1 Cidara Therapeutics, Inc. Profile

7.18.2 Cidara Therapeutics, Inc. Main Business

7.18.3 Cidara Therapeutics, Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.18.4 Cidara Therapeutics, Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.18.5 Cidara Therapeutics, Inc. Recent Developments

7.19 Amplyx Pharmaceuticals Inc.

7.19.1 Amplyx Pharmaceuticals Inc. Profile

7.19.2 Amplyx Pharmaceuticals Inc. Main Business

7.19.3 Amplyx Pharmaceuticals Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions

7.19.4 Amplyx Pharmaceuticals Inc. Drugs for Vaginal Fungal Infections Revenue (US$ Million) & (2019-2024)

7.19.5 Amplyx Pharmaceuticals Inc. Recent Developments

8 Industry Chain Analysis

8.1 Drugs for Vaginal Fungal Infections Industrial Chain

8.2 Drugs for Vaginal Fungal Infections Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Drugs for Vaginal Fungal Infections Sales Model

8.5.2 Sales Channel

8.5.3 Drugs for Vaginal Fungal Infections Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Pfizer Inc

Bausch Health Companies Inc.

Hikma Pharmaceuticals PLC

Lupin Ltd

Mycovia Pharmaceuticals, Inc

Glenmark Pharmaceuticals Limited

Unique Pharmaceuticals

PEPTONIC medical AB

Aurobindo Pharma Limited

Dr. Reddy’s Laboratories

Scynexis Inc

Basilea Pharmaceutica Ltd

Grupo Ferrer Internacional, S.A.

Pacgen Life Science Corporation

NovaDigm Therapeutics, Inc

Cidara Therapeutics, Inc

Amplyx Pharmaceuticals Inc

ANl Pharmaceuticals, Inc

Astellas Pharma lnc.

List of Tables

Table 1. Drugs for Vaginal Fungal Infections Market Trends

Table 2. Drugs for Vaginal Fungal Infections Market Drivers & Opportunity

Table 3. Drugs for Vaginal Fungal Infections Market Challenges

Table 4. Drugs for Vaginal Fungal Infections Market Restraints

Table 5. Global Drugs for Vaginal Fungal Infections Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Drugs for Vaginal Fungal Infections Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Drugs for Vaginal Fungal Infections Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Drugs for Vaginal Fungal Infections Product Type

Table 9. Key Companies Time to Begin Mass Production of Drugs for Vaginal Fungal Infections

Table 10. Global Drugs for Vaginal Fungal Infections Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Vaginal Fungal Infections as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Drugs for Vaginal Fungal Infections Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Drugs for Vaginal Fungal Infections Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Drugs for Vaginal Fungal Infections Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Drugs for Vaginal Fungal Infections Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Drugs for Vaginal Fungal Infections Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Drugs for Vaginal Fungal Infections Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Drugs for Vaginal Fungal Infections Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Drugs for Vaginal Fungal Infections Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Drugs for Vaginal Fungal Infections Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Drugs for Vaginal Fungal Infections Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Drugs for Vaginal Fungal Infections Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Drugs for Vaginal Fungal Infections Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Drugs for Vaginal Fungal Infections Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Drugs for Vaginal Fungal Infections Sales Value by Region (2019-2024) & (%)

Table 27. Global Drugs for Vaginal Fungal Infections Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Drugs for Vaginal Fungal Infections Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Drugs for Vaginal Fungal Infections Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Drugs for Vaginal Fungal Infections Sales Value, (2025-2030) & (US$ Million)

Table 31. Pfizer Inc. Basic Information List

Table 32. Pfizer Inc. Description and Business Overview

Table 33. Pfizer Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 34. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of Pfizer Inc. (2019-2024)

Table 35. Pfizer Inc. Recent Developments

Table 36. Bausch Health Companies Inc Basic Information List

Table 37. Bausch Health Companies Inc Description and Business Overview

Table 38. Bausch Health Companies Inc Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 39. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of Bausch Health Companies Inc (2019-2024)

Table 40. Bausch Health Companies Inc Recent Developments

Table 41. ANl Pharmaceuticals, Inc Basic Information List

Table 42. ANl Pharmaceuticals, Inc Description and Business Overview

Table 43. ANl Pharmaceuticals, Inc Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 44. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of ANl Pharmaceuticals, Inc (2019-2024)

Table 45. ANl Pharmaceuticals, Inc Recent Developments

Table 46. Hikma Pharmaceuticals Plc Basic Information List

Table 47. Hikma Pharmaceuticals Plc Description and Business Overview

Table 48. Hikma Pharmaceuticals Plc Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 49. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of Hikma Pharmaceuticals Plc (2019-2024)

Table 50. Hikma Pharmaceuticals Plc Recent Developments

Table 51. Lupin Limited Basic Information List

Table 52. Lupin Limited Description and Business Overview

Table 53. Lupin Limited Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 54. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of Lupin Limited (2019-2024)

Table 55. Lupin Limited Recent Developments

Table 56. Mycovia Pharmaceuticals, Inc. Basic Information List

Table 57. Mycovia Pharmaceuticals, Inc. Description and Business Overview

Table 58. Mycovia Pharmaceuticals, Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 59. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of Mycovia Pharmaceuticals, Inc. (2019-2024)

Table 60. Mycovia Pharmaceuticals, Inc. Recent Developments

Table 61. Glenmark Pharmaceuticals Limited Basic Information List

Table 62. Glenmark Pharmaceuticals Limited Description and Business Overview

Table 63. Glenmark Pharmaceuticals Limited Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 64. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of Glenmark Pharmaceuticals Limited (2019-2024)

Table 65. Glenmark Pharmaceuticals Limited Recent Developments

Table 66. Unique Pharmaceuticals Basic Information List

Table 67. Unique Pharmaceuticals Description and Business Overview

Table 68. Unique Pharmaceuticals Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 69. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of Unique Pharmaceuticals (2019-2024)

Table 70. Unique Pharmaceuticals Recent Developments

Table 71. PEPTONIC Medical AB Basic Information List

Table 72. PEPTONIC Medical AB Description and Business Overview

Table 73. PEPTONIC Medical AB Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 74. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of PEPTONIC Medical AB (2019-2024)

Table 75. PEPTONIC Medical AB Recent Developments

Table 76. Aurobindo Pharma Limited Basic Information List

Table 77. Aurobindo Pharma Limited Description and Business Overview

Table 78. Aurobindo Pharma Limited Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 79. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of Aurobindo Pharma Limited (2019-2024)

Table 80. Aurobindo Pharma Limited Recent Developments

Table 81. Dr. Reddy's Laboratories Basic Information List

Table 82. Dr. Reddy's Laboratories Description and Business Overview

Table 83. Dr. Reddy's Laboratories Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 84. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of Dr. Reddy's Laboratories (2019-2024)

Table 85. Dr. Reddy's Laboratories Recent Developments

Table 86. SCYNEXIS,Inc. Basic Information List

Table 87. SCYNEXIS,Inc. Description and Business Overview

Table 88. SCYNEXIS,Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 89. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of SCYNEXIS,Inc. (2019-2024)

Table 90. SCYNEXIS,Inc. Recent Developments

Table 91. Basilea Pharmaceutica Ltd. Basic Information List

Table 92. Basilea Pharmaceutica Ltd. Description and Business Overview

Table 93. Basilea Pharmaceutica Ltd. Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 94. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of Basilea Pharmaceutica Ltd. (2019-2024)

Table 95. Basilea Pharmaceutica Ltd. Recent Developments

Table 96. Astellas Pharma lnc. Basic Information List

Table 97. Astellas Pharma lnc. Description and Business Overview

Table 98. Astellas Pharma lnc. Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 99. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of Astellas Pharma lnc. (2019-2024)

Table 100. Astellas Pharma lnc. Recent Developments

Table 101. Grupo Ferrer Internacional,S.A. Basic Information List

Table 102. Grupo Ferrer Internacional,S.A. Description and Business Overview

Table 103. Grupo Ferrer Internacional,S.A. Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 104. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of Grupo Ferrer Internacional,S.A. (2019-2024)

Table 105. Grupo Ferrer Internacional,S.A. Recent Developments

Table 106. Pacgen Life Science Corporation Basic Information List

Table 107. Pacgen Life Science Corporation Description and Business Overview

Table 108. Pacgen Life Science Corporation Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 109. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of Pacgen Life Science Corporation (2019-2024)

Table 110. Pacgen Life Science Corporation Recent Developments

Table 111. NovaDigm Therapeutics, Inc. Basic Information List

Table 112. NovaDigm Therapeutics, Inc. Description and Business Overview

Table 113. NovaDigm Therapeutics, Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 114. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of NovaDigm Therapeutics, Inc. (2019-2024)

Table 115. NovaDigm Therapeutics, Inc. Recent Developments

Table 116. Cidara Therapeutics, Inc. Basic Information List

Table 117. Cidara Therapeutics, Inc. Description and Business Overview

Table 118. Cidara Therapeutics, Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 119. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of Cidara Therapeutics, Inc. (2019-2024)

Table 120. Cidara Therapeutics, Inc. Recent Developments

Table 121. Amplyx Pharmaceuticals Inc. Basic Information List

Table 122. Amplyx Pharmaceuticals Inc. Description and Business Overview

Table 123. Amplyx Pharmaceuticals Inc. Drugs for Vaginal Fungal Infections Products, Services and Solutions

Table 124. Revenue (US$ Million) in Drugs for Vaginal Fungal Infections Business of Amplyx Pharmaceuticals Inc. (2019-2024)

Table 125. Amplyx Pharmaceuticals Inc. Recent Developments

Table 126. Key Raw Materials Lists

Table 127. Raw Materials Key Suppliers Lists

Table 128. Drugs for Vaginal Fungal Infections Downstream Customers

Table 129. Drugs for Vaginal Fungal Infections Distributors List

Table 130. Research Programs/Design for This Report

Table 131. Key Data Information from Secondary Sources

Table 132. Key Data Information from Primary Sources

Table 133. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Drugs for Vaginal Fungal Infections Product Picture

Figure 2. Global Drugs for Vaginal Fungal Infections Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Drugs for Vaginal Fungal Infections Sales Value (2019-2030) & (US$ Million)

Figure 4. Drugs for Vaginal Fungal Infections Report Years Considered

Figure 5. Global Drugs for Vaginal Fungal Infections Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Drugs for Vaginal Fungal Infections Revenue in 2023

Figure 7. Drugs for Vaginal Fungal Infections Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Fluconazole Picture

Figure 9. Nystatin Picture

Figure 10. Flucytosine Picture

Figure 11. Clotrimazole Picture

Figure 12. Others Picture

Figure 13. Global Drugs for Vaginal Fungal Infections Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Drugs for Vaginal Fungal Infections Sales Value Market Share by Type, 2023 & 2030

Figure 15. Product Picture of Hospital

Figure 16. Product Picture of Clinic

Figure 17. Product Picture of Others

Figure 18. Global Drugs for Vaginal Fungal Infections Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 19. Global Drugs for Vaginal Fungal Infections Sales Value Market Share by Application, 2023 & 2030

Figure 20. North America Drugs for Vaginal Fungal Infections Sales Value (2019-2030) & (US$ Million)

Figure 21. North America Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030

Figure 22. Europe Drugs for Vaginal Fungal Infections Sales Value (2019-2030) & (US$ Million)

Figure 23. Europe Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030

Figure 24. Asia Pacific Drugs for Vaginal Fungal Infections Sales Value (2019-2030) & (US$ Million)

Figure 25. Asia Pacific Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030

Figure 26. South America Drugs for Vaginal Fungal Infections Sales Value (2019-2030) & (US$ Million)

Figure 27. South America Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030

Figure 28. Middle East & Africa Drugs for Vaginal Fungal Infections Sales Value (2019-2030) & (US$ Million)

Figure 29. Middle East & Africa Drugs for Vaginal Fungal Infections Sales Value by Country (%), 2023 VS 2030

Figure 30. Key Countries/Regions Drugs for Vaginal Fungal Infections Sales Value (%), (2019-2030)

Figure 31. United States Drugs for Vaginal Fungal Infections Sales Value, (2019-2030) & (US$ Million)

Figure 32. United States Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030

Figure 33. United States Drugs for Vaginal Fungal Infections Sales Value by Application (%), 2023 VS 2030

Figure 34. Europe Drugs for Vaginal Fungal Infections Sales Value, (2019-2030) & (US$ Million)

Figure 35. Europe Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030

Figure 36. Europe Drugs for Vaginal Fungal Infections Sales Value by Application (%), 2023 VS 2030

Figure 37. China Drugs for Vaginal Fungal Infections Sales Value, (2019-2030) & (US$ Million)

Figure 38. China Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030

Figure 39. China Drugs for Vaginal Fungal Infections Sales Value by Application (%), 2023 VS 2030

Figure 40. Japan Drugs for Vaginal Fungal Infections Sales Value, (2019-2030) & (US$ Million)

Figure 41. Japan Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030

Figure 42. Japan Drugs for Vaginal Fungal Infections Sales Value by Application (%), 2023 VS 2030

Figure 43. South Korea Drugs for Vaginal Fungal Infections Sales Value, (2019-2030) & (US$ Million)

Figure 44. South Korea Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030

Figure 45. South Korea Drugs for Vaginal Fungal Infections Sales Value by Application (%), 2023 VS 2030

Figure 46. Southeast Asia Drugs for Vaginal Fungal Infections Sales Value, (2019-2030) & (US$ Million)

Figure 47. Southeast Asia Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030

Figure 48. Southeast Asia Drugs for Vaginal Fungal Infections Sales Value by Application (%), 2023 VS 2030

Figure 49. India Drugs for Vaginal Fungal Infections Sales Value, (2019-2030) & (US$ Million)

Figure 50. India Drugs for Vaginal Fungal Infections Sales Value by Type (%), 2023 VS 2030

Figure 51. India Drugs for Vaginal Fungal Infections Sales Value by Application (%), 2023 VS 2030

Figure 52. Drugs for Vaginal Fungal Infections Industrial Chain

Figure 53. Drugs for Vaginal Fungal Infections Manufacturing Cost Structure

Figure 54. Channels of Distribution (Direct Sales, and Distribution)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions